Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancikova, Veronika, Smida, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197365/
https://www.ncbi.nlm.nih.gov/pubmed/34073911
http://dx.doi.org/10.3390/ijms22115536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197365/
https://www.ncbi.nlm.nih.gov/pubmed/34073911
http://dx.doi.org/10.3390/ijms22115536

Ejemplares similares